EGFR突变及VEGF表达与吉非替尼治疗晚期肺腺癌疗效关系的研究  

EGFR mutation and VEGF expression and relationship of effectiveness of gefitinib in patients with advanced lung adenocarcinoma

作　　者：周涛[1] 吕平 刘素勤[1] 班丽英[1] 

机构地区：[1]大连医科大学附属第一医院肿瘤科,辽宁大连116011 [2]朝阳市中心医院肿瘤科,辽宁朝阳122000

出　　处：《临床肺科杂志》2012年第12期2233-2234,共2页Journal of Clinical Pulmonary Medicine

基　　金：辽宁省教育厅2010年度高等学校科研计划项目基金资助(L2010121)

摘　　要：目的探讨EGFR突变及VEGF表达与吉非替尼治疗晚期肺腺癌疗效的关系。方法直接测序法检测30例晚期肺腺癌EGFR外显子19及21突变,免疫组化法检测VEGF表达,与吉非替尼疗效进行分析。结果 30例患者EGFR突变率46.7﹪(14/30),其中21外显子8例,19外显子6例;吉非替尼有效率50﹪,疾病控制率60.0﹪;15例有效患者EGFR突变率为80﹪,12例无效者为16.7%,差异显著(P=0.002);EGFR突变者中位无进展生存期为9.5个月,无突变者为1.5个月,差异有显著性(P<0.05)。有效患者VEGF的表达为(-)6例,(+)5例,(■)4例;无效患者为(-)1例,(+)2例,(■)3例,(■)4例,(■)2例,有效者VEGF表达低,差异显著(P<0.05)。VEGF表达与EGFR突变之间无相关性(P=0.104)。结论 EGFR突变者吉非替尼疗效好,VEGF低表达者吉非替尼疗效好。Objective To evaluate the relationship of EGFR mutation and VEGF expression and effectiveness of gefitinib in pa- tients with advanced lung adenocarcinoma. Methods EGFR exons 19 and 21 were detected using direct sequencing and VEGF expression were detected by IHC using paraffin embedded blocks from 30 patients who received first line gefitinib. Results EGFR mutation are found in 14 cases, included exon 21 8 cases and exon 19 6 cases. The overall response rate and disease controlled rate is 50. 0% and 60. 0% ; EGFR mutation of 15 effective cases is 80%, 12 cases non-effective is 16. 7%, the difference was significant （ P 〈 0. 05 ）. The median PFS is 9.5 months in mutation cases and 1.5 months without mutation, the difference is significant （ P 〈 O. 05）. In effective pa- tients, VEGF expression （ - ） is 6 cases, （ ＋ ） is 5 cases, （＋＋） is 4 cases, VEGF expression is lower than invalid cases （ P 〈 0.05 ）. No significant correlation between EGFR mutation and VEGF expression （P = 0. 104）. Conclusion EGFR mutation is a good predictor of gefitinib. Low VEGF expression can predict the effectiveness.

关 键 词：肺腺癌 吉非替尼 EGFR突变 VEGF 

分 类 号：R734.2[医药卫生—肿瘤]